Rare lephants
Screener

CV Sciences, Inc.

CVSI ·Healthcare, Drug Manufacturers - General, United States
Analysis › Company Overview

Business Overview: CV Sciences, Inc. (OTCQB: CVSI)

Executive Summary

CV Sciences is a small-cap consumer wellness company built around hemp-derived CBD (cannabidiol) products, anchored by its flagship PlusCBD brand — described by the company, citing SPINS data, as one of the top-selling hemp extract brands in the natural products market — alongside smaller plant-based food and pet-wellness brands. The company has been shrinking, not growing: fiscal 2025 total product sales fell to $13.8 million from $15.7 million in 2024, with gross margin of 49.0% ($6.8 million gross profit) and revenue split roughly 56% business-to-business and 44% business-to-consumer. CV Sciences has diversified somewhat beyond pure CBD through acquisitions — Cultured Foods (plant-based protein products, acquired December 2023) and Elevated Softgels (a Colorado-based softgel/tincture manufacturer, acquired May 2024) — and organic brand launches including +PlusHLTH (cannabinoid-free supplements, 2024) and Lunar Fox (plant-based products, March 2025), with 39% of 2025 revenue coming from products launched since January 2023.

The company's situation is financially precarious and increasingly shaped by adverse regulation rather than competitive dynamics: as of December 31, 2025, CV Sciences held only $278,000 in cash against negative operating cash flow of $407,000 for the year and an accumulated deficit of $87.9 million, with the company's own disclosures raising "substantial doubt" about its ability to continue as a going concern. Compounding this, newly enacted federal legislation will prohibit, effective November 13, 2026, the sale of hemp-derived products containing more than 0.4 milligrams of total THC per container — a rule that could eliminate a meaningful share of CV Sciences' existing PlusCBD product line — while California's emergency order banning detectable-THC hemp products for human use (in effect through an extended period into 2026) has already depressed the company's historically important California sales.

1. Core Business Model & How They Work

CV Sciences develops, manufactures (through owned and contracted facilities), and distributes hemp extract and plant-based wellness products through both business-to-business channels (wholesale to retailers and distributors, 56.1% of 2025 revenue) and business-to-consumer channels (direct online and retail sales, 43.9% of 2025 revenue). The core product, PlusCBD, spans softgels, tinctures, topicals, and gummies formulated with hemp-derived CBD extract, sold on wellness claims around relaxation, sleep, and general well-being rather than any FDA-approved therapeutic indication — a crucial distinction, since the FDA currently deems the addition of CBD to food or beverages illegal, constraining how CV Sciences and the broader industry can market and distribute these products.

The company's 2023-2025 acquisitions reflect a deliberate attempt to diversify revenue beyond pure CBD into adjacent wellness categories less exposed to CBD-specific regulatory risk: Cultured Foods brought plant-based protein products, and the Lunar Fox launch extended into broader plant-based foods, particularly targeting the European market where CV Sciences notes most competitors sell refrigerated products while its own offerings are shelf-stable — a logistics and distribution advantage in that specific niche. Manufacturing now spans San Diego, California (historic headquarters), Grand Junction, Colorado (via the Elevated Softgels acquisition), and Warsaw, Poland (supporting European plant-based food distribution).

Key Operational Drivers

  1. Federal and State THC Regulatory Risk — the single most consequential near-term factor: the federal 0.4mg total-THC-per-container limit taking effect November 13, 2026 threatens to restrict or eliminate existing PlusCBD formulations, while California's hemp product ban has already suppressed sales in a historically important state market.
  2. Cash Runway and Going-Concern Risk — with only $278,000 in cash and negative operating cash flow against an $87.9 million accumulated deficit, CV Sciences' ability to continue operating depends on near-term financing, cost reduction, or a strategic transaction.
  3. New Product Diversification (39% of Revenue from Post-2023 Launches) — the company's push into +PlusHLTH (cannabinoid-free), Cultured Foods (plant protein), and Lunar Fox (plant-based foods) reflects a strategy to reduce dependence on CBD-specific products ahead of the 2026 regulatory change.
  4. B2B vs. B2C Channel Mix — the roughly 56%/44% B2B/B2C split means CV Sciences depends significantly on retailer and distributor relationships (subject to their own purchasing and shelf-space decisions) in addition to its own direct-to-consumer sales execution.
  5. Manufacturing Integration via Elevated Softgels — bringing softgel/tincture manufacturing in-house via the May 2024 acquisition gives CV Sciences more control over cost and quality for its core PlusCBD product lines, reducing reliance on third-party contract manufacturers.

2. Business Segments

CV Sciences does not report formal multi-segment financials; it operates as a single consumer products company with revenue analyzed by brand/product category (PlusCBD and PlusCBD Pet hemp extracts, +PlusHLTH cannabinoid-free supplements, Cultured Foods and Lunar Fox plant-based foods) and by channel (B2B wholesale/distribution versus B2C direct sales).

3. Product Portfolio

  • PlusCBD — softgels, tinctures, topicals, and gummies; the company's flagship, top-selling hemp extract brand.
  • PlusCBD Pet — CBD formulations for cats and dogs.
  • +PlusHLTH — cannabinoid-free supplements, launched 2024 as a regulatory-risk hedge.
  • Cultured Foods — plant-based protein products, acquired December 2023.
  • Lunar Fox — plant-based food products, launched March 2025, targeting the shelf-stable niche in the European plant-based food market.

4. Competitive Landscape

In hemp/CBD wellness products, CV Sciences competes in a market it describes as "highly competitive and fragmented," against named competitors Charlotte's Web Holdings and cbdMD, as well as Medterra CBD — all similarly scaled, publicly traded or formerly-public CBD wellness brands facing comparable regulatory headwinds. In the plant-based food category (via Cultured Foods and Lunar Fox), the European market is "similarly fragmented," but CV Sciences highlights that most competitors there sell refrigerated products while its own offerings are shelf-stable, a specific logistical/distribution differentiation versus the broader competitive set rather than a brand- or scale-based advantage.

5. Strategic Strengths & Risks

Strengths: PlusCBD's recognized position as a top-selling hemp extract brand (per SPINS data) provides real brand equity in a crowded category, and the company's diversification into cannabinoid-free (+PlusHLTH) and plant-based food products (Cultured Foods, Lunar Fox) demonstrates a proactive attempt to reduce single-category regulatory exposure ahead of the 2026 federal THC rule change. Vertical integration of softgel/tincture manufacturing via Elevated Softgels gives some cost and quality control advantage for core products.

Risks: The company's financial position is severe — $278,000 in cash, negative operating cash flow, an $87.9 million accumulated deficit, and explicit going-concern doubt — meaning CV Sciences may not survive as an independent company absent new financing or a strategic transaction. The looming federal 0.4mg total-THC-per-container limit (effective November 13, 2026) is a near-term existential threat to the PlusCBD product line as currently formulated, and California's ongoing hemp product restrictions have already measurably hurt sales in a key state market. Revenue has declined for at least two consecutive years ($15.7 million in 2024 to $13.8 million in 2025), showing the diversification efforts have not yet offset core CBD category pressure.

6. Financial Overview

Fiscal 2025 total product sales were $13.8 million (down from $15.7 million in 2024), with gross profit of $6.8 million (49.0% margin). Revenue split approximately 56.1% B2B ($7.7 million) and 43.9% B2C ($6.0 million). Operating cash flow was negative $407,000 for the year, cash on hand was just $278,000 as of December 31, 2025, and the accumulated deficit stood at $87.9 million — collectively supporting management's own disclosure of substantial doubt about the company's ability to continue as a going concern.

7. Summary Conclusion

CV Sciences holds a recognized brand position in a shrinking, increasingly regulated hemp-CBD category, and has made deliberate moves to diversify into cannabinoid-free supplements and plant-based foods ahead of a federal THC rule change that takes effect in November 2026. However, the company's severely constrained cash position, continuing revenue decline, and explicit going-concern disclosure mean that near-term survival — not competitive positioning — is the dominant question for any investor evaluating CVSI today.